Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience
- 1UOC DERMATOLOGIA ‘Daniele Innocenzi’-ASL LATINA Sapienza Università di Roma-Polo Pontino, Corso della Repubblica, 79, 04100 Latina, Italy
Abstract
Psoriasis is often associated with obesity and type 2 diabetes mellitus (T2DM) due to a common low-grade chronic inflammatory mechanism amplified by metabolic dysfunction. Biologics have revolutionized psoriasis treatment, but patients with obesity show reduced responses and higher discontinuation rates. Glucagon-like peptide-1 receptor agonists—such as semaglutide—may enhance the efficacy of psoriasis care; however, data are limited in this context. We presented a retrospective analysis of our single-center real-world experience with 33 obese patients (24 men and 9 women) affected by mild (n = 19, 57.6%) or moderate (n = 14, 42.4%) psoriasis and treated with semaglutide over 18 months. Adherence to the semaglutide prescription was 94% (range 88–99%), with most patients (54.5%) having a last recorded dose of 1.0 mg. A significant mean reduction of 4.25 points in the PASI score (from 9.31 ± 1.54 to 5.05 ± 0.88; p < 0.001) was reported, followed by a mean decrease of 4.15 kg/m2 in BMI (from 32.53 ± 1.92 to 28.38 ± 1.59 kg/m2; p < 0.001) and significant improvements in all metabolic parameters. In addition, there was a significant decrease in inflammatory markers (CRP decreased from 5.47 ± 1.69 to 2.69 ± 0.94 mg/L, and ESR from 17.76 ± 4.22 to 11.64 ± 2.83 mm/h). More than fifty-seven percent (57.6%) of patients experienced mild and transitory gastrointestinal reactions, but no cases of discontinuation or cutaneous reaction occurred. Data provide additional insights into the role of semaglutide in patients with mild-to-moderate psoriasis. Large-scale, multicenter studies are needed to validate long-term results.
Related
- Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience.
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity
- Unaltered expression of the lncRNA NRON in lesional skin from patients with psoriasis.
- Reframing the lived experience of persistent dizziness: insights from active inference.
- T cells form distinct spatially restricted immune responses in synovium of patients with psoriasis arthritis and rheumatoid arthritis
BibTeX
@article{proietti2026semaglutide,
title = {{Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience}},
author = {Ilaria Proietti and Concetta Potenza},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208015},
url = {https://www.mdpi.com/2077-0383/15/20/8015},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Semaglutide in Patients with Obesity and Psoriasis: Insights from an 18-Month Real-World Experience
AU - Ilaria Proietti
AU - Concetta Potenza
PY - 2026
DA - 2026/10/16
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208015
UR - https://www.mdpi.com/2077-0383/15/20/8015
AB - Psoriasis is often associated with obesity and type 2 diabetes mellitus (T2DM) due to a common low-grade chronic inflammatory mechanism amplified by metabolic dysfunction. Biologics have revolutionized psoriasis treatment, but patients with obesity show reduced responses and higher discontinuation rates. Glucagon-like peptide-1 receptor agonists—such as semaglutide—may enhance the efficacy of psoriasis care; however, data are limited in this context. We presented a retrospective analysis of our single-center real-world experience with 33 obese patients (24 men and 9 women) affected by mild (n = 19, 57.6%) or moderate (n = 14, 42.4%) psoriasis and treated with semaglutide over 18 months. Adherence to the semaglutide prescription was 94% (range 88–99%), with most patients (54.5%) having a last recorded dose of 1.0 mg. A significant mean reduction of 4.25 points in the PASI score (from 9.31 ± 1.54 to 5.05 ± 0.88; p < 0.001) was reported, followed by a mean decrease of 4.15 kg/m2 in BMI (from 32.53 ± 1.92 to 28.38 ± 1.59 kg/m2; p < 0.001) and significant improvements in all metabolic parameters. In addition, there was a significant decrease in inflammatory markers (CRP decreased from 5.47 ± 1.69 to 2.69 ± 0.94 mg/L, and ESR from 17.76 ± 4.22 to 11.64 ± 2.83 mm/h). More than fifty-seven percent (57.6%) of patients experienced mild and transitory gastrointestinal reactions, but no cases of discontinuation or cutaneous reaction occurred. Data provide additional insights into the role of semaglutide in patients with mild-to-moderate psoriasis. Large-scale, multicenter studies are needed to validate long-term results.
SN - 2077-0383
ER -